Diabetes cell therapy - Diatranz Otsuka Limited

Drug Profile

Diabetes cell therapy - Diatranz Otsuka Limited

Alternative Names: DiabeCell®; Immunoprotected (alginate-encapsulated) porcine islets - Diatranz Otsuka Limited

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Living Cell Technologies
  • Developer Diatranz Otsuka Limited; Living Cell Technologies; Otsuka Pharmaceutical Factory Inc
  • Class Antihyperglycaemics; Cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Type 1 diabetes mellitus

Most Recent Events

  • 05 Oct 2017 Discontinued - Registered for Type-1 diabetes mellitus in Russia (Intraperitoneal) before October 2017, because no recent reports on development were identified and Diatranz Otsuka Limited is focussing its efforts on development in USA
  • 05 Oct 2017 Diatranz Otsuka Limited plans a phase II/III trial for Type 1 diabetes mellitus in USA (Diatranz Otsuka Limited website, October 2017)
  • 25 Mar 2015 No recent reports of development identified - Registered for Type-1 diabetes mellitus in Russia (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top